About Careers MedBlog Contact us

New Drug, Pembrolizumab, Shows Promising Results for Triple-Negative Breast Cancer Patients

by Dr. Trupti Shirole on December 11, 2014 at 7:33 AM
Font : A-A+

 New Drug, Pembrolizumab, Shows Promising Results for Triple-Negative Breast Cancer Patients

Infusion of pembrolizumab (MK-3475) produced durable responses in almost one out of five patients with metastatic triple-negative breast cancer. The disease has no approved targeted therapies.

The multi-center, non-randomized phase-Ib clinical trial was designed to evaluate the safety, tolerability and antitumor activity of bi-weekly infusions of pembrolizumab. 27 patients, aged 29-72 years, with metastatic triple-negative breast cancer that had either relapsed after treatment for early stage disease or progressed on therapy for advanced disease, were part of the trial.


The metastatic triple-negative tumors have high levels of a protein called programmed death-ligand 1 (PD-L1), which can suppress the immune system's efforts to eliminate cancer cells. Pembrolizumab, a monoclonal antibody, is designed to help reactivate a person's own immune system to help fight the tumor.   

Study director Rita Nanda, MD, assistant professor of medicine and associate director of the breast medical oncology program at the University of Chicago, said, "Of the 27 patients in this study with measurable disease, five (18.5%) had encouraging results. One patient had a complete response, and four had a partial response to treatment."

Pembrolizumab was approved by the Food and Drug Administration for treatment of melanoma in September 2014. It has side-effects like fatigue, cough, nausea, itchy skin, rash, decreased appetite, constipation, joint pain and diarrhea; which are generally mild and easy to tackle. During the trial 4 of the 27 patients experienced at least one severe or life-threatening drug-related adverse event. One patient died while on the study treatment.  

An earlier study of pembrolizumab by Dr. Tanguy Seiwert, MD, assistant professor of medicine at the University of Chicago, found a similar response rate in PD-L1 positive patients with advanced head and neck cancer.  

The median survival for patients with triple-negative breast cancer is approximately a year and better treatments are needed to manage the disease. The promising activity of pembrolizumab is certainly worthy of further investigation. Researchers are looking forward to learn how to predict which patients are most likely to benefit and how to manage the drug's toxicity.

Source: Medindia


Recommended Reading

Latest Clinical Trials News

Parkinson's Disease Drug Ropinirole Slows Progression of ALS
Amyotrophic lateral sclerosis patients' motor neurons responded robustly to Parkinson's drug ropinirole.
 Nanorobots: A Revolutionary Tool in Targeting Fungal Infections
A new way to quickly eliminate fungal infections in the mouth has been developed by researchers at Penn Dental and Penn Engineering, using magnetically guided nanorobots.
 Gene Therapy Using Adeno Virus Reverses Age-Related Hearing Loss
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
Stickers Promise a Painless Mode of Measles Vaccine Delivery
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
 New Wearable Ultrasound Device Monitors Deep-Tissues in Moving Subjects
Scientists devise a fully integrated autonomous wearable ultrasonic-system-on-patch to sense deep tissue vital signs wirelessly even when the patient is on the move.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Drug, Pembrolizumab, Shows Promising Results for Triple-Negative Breast Cancer Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests